Category and country
Research companies in Germany
5 research profiles in Germany. Every profile is hand-reviewed with leadership, certifications, and public sources.
Where does research cluster in Germany?
Berlin (2), Heidelberg (2), and Hamburg (1) Most visible profiles: TissUse, German Cancer Research Center, EMBL Heidelberg, and Max Delbruck Center Berlin-Buch.
Which standards are already visible?
GLP (4) Latest review: 22 March 2026. Review cycle: March 2026.
Full list
Research profiles in Germany
5 profiles match the active filter.
Current review cycle
TissUse
BerlinGermanyResearch
Berlin organ-on-chip company developing multi-organ microphysiological systems for drug development, toxicology, and advanced human tissue models.
- Lead
- Uwe MarxChief Executive Officer
- Scale
- Research-platform operations
Current review cycle
German Cancer Research Center
HeidelbergGermanyResearch
Heidelberg cancer-research flagship integrating oncologic discovery, prevention, translational programmes, and national research infrastructure.
- Lead
- Prof. Dr. Michael BaumannChairman and Scientific Director
- Scale
- Large national oncology-research centre
Current review cycle
EMBL Heidelberg
HeidelbergGermanyResearch
Heidelberg European molecular-biology site linking structural biology, genomics, data, and international training infrastructure into the wider cluster.
- Lead
- Jan KorbelInterim Head of Site, EMBL Heidelberg
- Scale
- European molecular-biology flagship site
Current review cycle
Max Delbruck Center Berlin-Buch
BerlinGermanyResearch
Berlin-Buch biomedical research centre combining disease-biology programmes, technology platforms, and translational partnerships across the German capital region.
- Lead
- Prof. Dr. Maike SanderChair of the Board and Scientific Director
- Scale
- Large biomedical research centre
Current review cycle
Evotec
HamburgGermanyResearch
Hamburg discovery and development platform spanning integrated R&D, translational biology, and industrialized biotech partnerships.
- Lead
- Dr. Christian WojczewskiChief Executive Officer and Chair of the Management Board
- Scale
- Global research platform
Related brief
Read deeper on this category
EU Biotech Regulation 2026: What Changed and Who It Affects
A plain reading of the 2026 EU biotech regulatory package — pharmaceutical reform, the European Health Data Space, the AI Act, and the upcoming EU Biotech Act — and what biotech, pharma, and CDMO companies should do about it.
Open briefFAQ
Frequently asked questions on this category
- What is the difference between research and discovery in this directory?
- Research = institutional capacity (universities, public institutes, translational centers, science parks). Drug Discovery = company-owned IP and pipelines. A research institute generates fundamental knowledge and may translate it into spin-outs; a discovery company commercializes specific candidates.
- Which European institutions lead biotech research?
- Germany hosts the deepest non-profit infrastructure (DKFZ, MDC, Helmholtz Munich, MPI). Switzerland: ETH Zurich, EPFL, Roche Innovation Center. Sweden: Karolinska Institutet, SciLifeLab. Lithuania: Vilnius University Life Sciences Center. Estonia: University of Tartu, Estonian Genome Project. Each institution interfaces with the surrounding industry via translational programs.
- How are research organizations verified in this directory?
- Every profile is hand-reviewed: institutional identity confirmed by primary source, physical site address sourced from official disclosures, research focus and program scope backed by published documentation, and a registry note explaining current research focus and industry-relevance.
Next step
Compare companies or open the wider market.
Use the compare tool to view two or three companies side by side, or open the country hub for the full market view.